AAT, AACT and STIP1, in pre- and post-treatment CP-CML subjects was also not different from the above two markers; their ANOVA p-value was, however, higher than 0.0001 (Fig. 3D–F). This evidence concerns the gene STIP1 and chronic myelogenous leukemia, BCR-ABL1 positive.